Venlafaxine

Research use only, not for human use.

Venlafaxine, an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), is used to treat major generalised anxiety disorder (GAD), depressive disorder (MDD), panic disorder and social phobia.

Venlafaxine, an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), is used to treat major generalised anxiety disorder (GAD), depressive disorder (MDD), panic disorder and social phobia.

Venlafaxine (Wy 45030) dose-dependently inhibits binding of the serotonin transporter radioligand [3H]-paroxetine to membranes from cells transfected with the human 5-HT transporter with a Ki of 2.48 μM. Venlafaxine inhibits binding of the NE transporter ligand [3H]-nisoxetine to membranes from cells transfected with the human NE transporter with a Ki of 82 nM.Venlafaxine inhibits ex vivo binding to rat 5-HT transporters and NE transporters with ED50 values of 2 and 54 mg/kg, respectively.

Venlafaxine (Wy 45030; 10-100 mg/kg; IP) dose-dependently blocks the depletion of norepinephrine levels in rat hypothalamus induced by 6-OHDA. Animal Model:Male Sprague-Dawley rats weighing 180-230 gramsDosage:10, 30, 100 mg/kg Administration:IP; one hour prior to p-chloramphetamine hydrochloride (p-CA; 10 mg/kg; i.p.)Result:Dose-dependently blocked the depletion of norepinephrine levels in rat hypothalamus induced by 6-OHDA (intracerebroventricularly; 50 μg/rat; one hour later), with ED50 values of 12 and 94 mg/kg, respectively.

Wy 45030

Others

Other Targets

serotonin-norepinephrine reuptake

nervous system

Panic Disorder

93413-69-5

277.4

C17H27NO2

>98% (HPLC)

DMSO:52 mg/mL (187.45mM)

COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1

——

(-20℃)

With Ice Pack

≥ 2 years